RevCore device is designed to address venous in-stent thrombosis and the Triever16 Curve catheter has been designed to be adaptable for both peripheral thrombectomy and pulmonary embolism
Inari Medical announces the commercial launch of the RevCore and Triever16 Curve catheters. (Credit: Hush Naidoo Jade Photography on Unsplash)
US-based medical device company Inari Medical has commercially launched its new RevCore thrombectomy catheter and the Triever16 Curve catheter for addressing venous stent thrombosis and venous thromboembolism.
RevCore is said to be the first mechanical thrombectomy device to address venous in-stent thrombosis. It has a diameter-controlled coring element made to safely engage thrombus inside stents.
With the RevCore thrombectomy catheter, Inari Medical claims to have developed a solution for a whole new patient population that the ClotTriever and FlowTriever platforms do not currently serve.
MedStar Health, Washington, DC, vascular surgery chair Steven Abramowitz said: “RevCore is a game changer as it physically removes in-stent thrombus, restores flow, and could potentially reduce the need for additional reintervention.
“There are a lot of patients out there that may benefit from the RevCore procedure.”
The newest addition to the FlowTriever platform, the Triever16 Curve catheter, has been created to be adaptable for both peripheral thrombectomy and pulmonary embolism.
A pre-shaped curve is present on the trackable catheter to allow for targeted aspiration, the medical device firm said.
The new catheter is said to have unique advantages over 16F continuous aspiration catheters. These include compatibility with the FlowSaver blood return device and simple access to 20F or 24F catheters within the price-per-procedure model of Inari Medical.
Inari Medical CEO Drew Hykes said: “We are thrilled to announce the commercial launch of these two products, which reinforce our unwavering commitment to addressing unmet needs with purpose-driven innovation.
“We continue to push the boundaries, and we are excited about the potential impact we can make on patients’ lives with these products and beyond.”
In January this year, the medical device company enrolled the first patient in the DEFIANCE trial of its ClotTriever System in patients with iliofemoral deep vein thrombosis (DVT).